The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vlasov P.N.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii", Moskva

Orekhova N.V.

Kafedra nervnykh bolezneĭ lechebnogo fakul'teta Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

The 'cost-benefit' analysis of new antiepileptic drugs

Authors:

Vlasov P.N., Orekhova N.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(10): 39‑43

Read: 822 times

Download PDF (RU)
Contact the author
Table of contents

THE 'COST-BENEFIT' ANALYSIS OF NEW ANTIEPILEPTIC DRUGS
THE 'COST-BENEFIT' ANALYSIS OF NEW ANTIEPILEPTIC DRUGS

To cite this article:

Vlasov PN, Orekhova NV. The 'cost-benefit' analysis of new antiepileptic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(10):39‑43. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Auto­nomic cardiovascular diso­rders in patients with epileptic and psychogenic non-epileptic seizures: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):13-20
The pote­ntial of cortical electrical stimulation for the study of auto­nomic dysfunction in patients with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):25-34
The role of neuroinflammation in the deve­lopment of seizure acti­vity and auto­nomic diso­rders in patients with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):50-58
Epileptogenesis and risk factors of symptomatic epileptic seizures in patients with acute cere­brovascular acci­dents. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):26-31
The rela­tionship between the inte­rictal para­meters of cardiovascular auto­nomic regu­lation and the outcomes of surgical treatment of epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):50-59
Economic issues of medi­cal care for hype­rparathyroidism. Part 1. Primary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):51-61
A personalized approach to the diagnosis of epilepsy in obese children. Labo­ratory Service. 2025;(1):5-12
Post-exposure prophylaxis of influenza and ARVI. Resu­lts of a double-blind, placebo-controlled clinical trial of Meglumine acri­done acetate and its pharmacoeconomic rationale. Russian Journal of Preventive Medi­cine. 2025;(4):57-66
Economics of hype­rparathyroidism. Part 2 — seco­ndary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):74-82
Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):83-92
Abstract:

The objective was to optimize the pharmaceutical treatment of epileptic patients and to evaluate the clinical-economical effectiveness of new antiepileptic drugs (AED) - levetiracetam, lamotrigine, topiramate and oxcarbazepine. The study included 134 patients with different types of seizures who received earlier antiepileptics with the addition of new AED as mono- or polytherapy. The cost of treatment and pharmacoeconomic "cost-benefit" index were calculated before and after the treatment optimization. After one year of the treatment with "new" AED, the decrease in seizure frequency was 75-92%. The "cost-benefit" ratio was significantly (p<0,05) decreased by 2-3 times in all types of seizures despite the increase of direst costs of the treatment. The significant (p<0,05) decrease in the cost of treatment of epilepsy was noted in all groups studied. In conclusion, the rational treatment using "new" AED allows to reduce both the total cost of treatment and "cost-benefit" ratio.

Keywords:

epilepsy
levetiracetam
lamotrigine
topiramate
oxcarbazepine
pharmacoeconomics
'cost-benefits'

Authors:

Vlasov P.N.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii", Moskva

Orekhova N.V.

Kafedra nervnykh bolezneĭ lechebnogo fakul'teta Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Close metadata

References:

  1. Beketov A.S. Provedenie analiza "tsena-effektivnost'" dlya vybora preparatov iz gruppy analogov. Kachestvennaya klinicheskaya praktika 2002; 2: 49-5
  2. Vlasov P.N., Orekhova N.V., Leonova M.V. Farmakoekonomicheskii analiz "stoimost'-effektivnost'" v otsenke rezul'tativnosti lecheniya epilepsii u vzroslykh. Nevrologiya, neiropsikhiatriya, psikhosomatika 2010; 2: 66-70.
  3. Leonova M.V., Vlasov P.N., Filatova N.V., Orekhova N.V. Epilepsiya u vzroslykh v aspekte stoimosti zabolevaniya. Epilepsiya. Zhurn nevrol i psikhiat 2010; 3: 44-47.
  4. Blais L., Sheehy O., St-Hilaire J.M. et al. Research Centre, University of Montreal Hospital, Montreal, Quebec, Canada. Source Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. Pharmacoeconomics 2005; 23: 5: 493-503.
  5. Guk-Hee Suh, Sang Keol Lee Economic Evaluation of Add-on Levetiracetam for the Treatment of Refractory Partial Epilepsy in Korea. Psychiatry Investigation 2009; 6: 3: 185-193.
  6. Jacques Le Lorier, Philippe Godfroid, Yvonne Hart, Richard Roberts Levetiracetam: an innovative and cost-effective add-on drug for refractory partial epilepsy. Expert Review of Pharmacoeconomics & Outcomes Research 2004; 4: 2: 143-151.
  7. Messori A., Trippoli S., Becagli P. et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998; 53: 6: 421-427.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.